ARTICLE | Clinical News
Evolva Holding preclinical data
September 17, 2012 7:00 AM UTC
In a mouse model of melioidosis, analogs of EV-035 led to 21-day survival rates of 87.5% when given alone and 75% when given in combination with ceftazidime vs. 12.5% for vehicle-treated controls. In ...